GuidelineStroke and vascular neurology2017
The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke.
Guideline in Stroke and vascular neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07045987 (FUtile Reperfusion in acuTe iscHEmic stRoke- FURTHER), which is not on this map. Cited by 53 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FUtile Reperfusion in acuTe iscHEmic stRoke- FURTHER
Who cites it
53 citing papers in PubMed, 6 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Intravenous thrombolysis versus antiplatelet standard care for patients with mild acute ischemic stroke: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of anisodine hydrobromide injection for acute ischemic stroke: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Systematic Review of Existing Stroke Guidelines: Case for a Change.BioMed research international · 2022Pooled it
- Reporting quality evaluation of the stroke clinical practice guidelines: a systematic review.Systematic reviews · 2021Pooled it
- Quality of stroke guidelines in low- and middle-income countries: a systematic review.Bulletin of the World Health Organization · 2021Pooled it
- Head-to-Head: Recombinant Human Prourokinase Versus Intravenous Thrombolytics in Acute Ischemic Stroke Within 4.5 Hours - A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial.Stroke and vascular neurology · 2025Trial
- Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial.BMC medicine · 2025Trial
- Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial.Stroke and vascular neurology · 2024Trial
- Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia.Journal of the American Heart Association · 2024Trial
- Impact of antithrombotic therapy on outcomes of incidental unruptured intracranial aneurysms in patients with ischemic stroke.Annals of medicine · 2026Article
- Efficacy and safety of early tirofiban administration after intravenous thrombolysis in patients with acute ischaemic stroke: the multicentre, randomised, double-blind, placebo-controlled RESCUE BT3 trial protocol.European stroke journal · 2026Article
- Article
- Association between glucose-to-albumin ratio and ischemic stroke risk in patients with coronary heart disease: a machine learning-based predictive model analysis.BMC cardiovascular disorders · 2025Article
- A similar effect of fibrinogen on efficacy and safety of tenecteplaseJournal of translational internal medicine · 2025Article
- Decomposing door-to-needle time: insights into workflow delays and quality improvement in acute stroke care.Frontiers in neurology · 2025Article
- Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours (RAISE): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial.Stroke and vascular neurology · 2024Article
- Tenecteplase Versus Alteplase in Acute Ischemic Stroke in Chinese Patients: Protocol for the ORIGINAL Study.Stroke (Hoboken, N.J.) · 2024Article
- Code Stroke Alert: Focus on Emergency Department Time Targets and Impact on Door-to-Needle Time across Day and Night Shifts.Journal of personalized medicine · 2024Article
- Mechanism of acupuncture in attenuating cerebral ischaemia-reperfusion injury based on nuclear receptor coactivator 4 mediated ferritinophagy.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate of intravenous tissue plasminogen activator usage was only about 1.6% in real world. The indication of thrombolysis for AIS has been expanded, and contraindications have been reduced with recently published studies. In order to facilitate the standardisation of treating AIS, improve the rate of thrombolysis and benefit patients who had a stroke, Chinese Stroke Association has organised and developed this scientific statement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.